Skip to main content
  • U.S. Department of Health & Human Services
National Institutes of Health (NIH) - Turning Discovery into Health
  • Virtual Tour
  • En Español

Site Menu

  • Home
  • Health Information
    • Health Care Providers & Facilities
    • Health Info Lines
    • HealthCare.gov
    • Science Education Resources
    • NIH Clinical Research Trials and You
    • Talking to Your Doctor

    More »

    Quick Links

    • MedlinePlus Health Info
    • NIH News in Health
    • Wellness Toolkits
  • Grants & Funding
    • Grants Home Page
    • Find Funding
    • Due Dates
    • How to Apply
    • About Grants
    • Policy & Compliance
    • Grants News/Blog
    • Contracts
    • Loan Repayment

    More »

    Quick Links

    • RePORT
    • eRA Commons
    • NIH Common Fund
  • News & Events
    • News Releases
    • Digital Media Kits
    • Media Resources
    • Media Contacts
    • Images and B-roll
    • Events
    • Social Media

    More »

    Quick Links

    • NIH News in Health
    • NIH Research Matters
    • NIH Record
  • Research & Training
    • Medical Research Initiatives
    • Science Highlights
    • Science Education
    • Research in NIH Labs & Clinics
    • Training Opportunities
    • Library Resources
    • Research Resources
    • Clinical Research Resources
    • Safety, Regulation and Guidance

    More »

    Quick Links

    • PubMed
    • Stem Cell Information
    • OppNet
    • NIDB
    • NIH Blueprint for Neuroscience Research
  • Institutes at NIH
    • List of Institutes and Centers
    • NIH Office of the Director
    • Directors of NIH Institutes and Centers
    • NIH Institute and Center Contact Information

    More »

    Quick Links

    • NCI
    • NEI
    • NHLBI
    • NHGRI
    • NIA
    • NIAAA
    • NIAID
    • NIAMS
    • NIBIB
    • NICHD
    • NIDCD
    • NIDCR
    • NIDDK
    • NIDA
    • NIEHS
    • NIGMS
    • NIMH
    • NIMHD
    • NINDS
    • NINR
    • NLM
    • CC
    • CIT
    • CSR
    • FIC
    • NCATS
    • NCCIH
  • About NIH
    • Who We Are
    • What We Do
    • Jobs at NIH
    • Visitor Information
    • Frequently Asked Questions
    • Contact Us

    More »

    Quick Links

    • The NIH Director
    • Take the Virtual Tour
    • NIH…Turning Discovery Into Health®
    • Impact of NIH Research
    • Science, Health, and Public Trust

You are here

Home » News & Events » News Releases

News Releases

News Release

Thursday, April 2, 2020

NIDA Director outlines potential risks to people who smoke and use drugs during COVID-19 pandemic

The piece raises several important concerns regarding COVID-19 for specific vulnerable populations.

Novel Coronavirus SARS-CoV-2 Colorized scanning electron micrograph of an apoptotic cell (red) heavily infected with SARS-COV-2 virus particles (yellow), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. NIAID

What

The precarious intersection of the COVID-19 national health emergency and the concurrent epidemic of drug overdose deaths is outlined in the Annals of Internal Medicine this week by Dr. Nora D. Volkow, director of the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. Dr. Volkow discusses how the serious health risks of COVID-19 pose unique challenges to people who smoke or vape, are already struggling with substance use disorders (SUD), or are in recovery from addiction. 

The Ideas and Opinions piece raises several important concerns regarding COVID-19 for specific vulnerable populations, including:

  • Patients with already compromised lung conditions may be at higher risk for more severe complications from COVID-19. Specifically, people who smoke or vape, or use opioids or methamphetamine may face heightened risk. In addition, chronic opioid use already increases the risk of slowed breathing due to hypoxemia, which can lead to cardiac and pulmonary complications that may result in overdose and death. While all people should be taking precautions to prevent exposure to COVID-19, this is particularly critical for higher risk groups, including people who smoke, vape, or use opioids or methamphetamine. Dr. Volkow urges clinicians to be alert to the possibility of increased risks for adverse COVID-19 outcomes in these patients. 
  • People recovering from addiction now face new challenges. Physical distancing measures, while critical to COVID-19 mitigation, eliminate the important element of social support needed for addiction recovery. Additionally, people with opioid use disorder may face barriers to obtaining medications (i.e., buprenorphine or methadone) or obtaining services from syringe services programs.
  • Social distancing will also decrease the likelihood of observed overdoses; administration of naloxone to reverse overdose may be less likely, potentially resulting in more fatalities.
  • Dr. Volkow lauds efforts by the public health community to reduce new challenges for people in recovery, including the deployment of virtual support meetings for those with internet access and the possibility of take-home medications for some people in addiction treatment. Above all, Dr. Volkow stresses that, like other vulnerable people in the United States, people with SUD cannot be forgotten or marginalized during this crisis.

Who

 To schedule an interview with Dr. Volkow, please contact media@nida.nih.gov or 301-443-6245.

Article

Annals of Internal Medicine, go to: Collision of the COVID-19 and Addiction Epidemics https://annals.org/aim/fullarticle/2764313/collision-covid-19-addiction-epidemics  

For more information, NIDA has a web page dedicated to COVID-19 resources for people in addiction treatment or recovery.

The National Institute on Drug Abuse (NIDA) is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to inform policy and improve practice. Fact sheets on the health effects of drugs of abuse and information on NIDA research and other activities can be found at https://www.drugabuse.gov, which is now compatible with your smartphone, iPad or tablet. To order publications in English or Spanish, call NIDA’s DrugPubs research dissemination center at 1-877-NIDA-NIH or 240-645-0228 (TDD) or email requests to drugpubs@nida.nih.gov. Online ordering is available at https://drugpubs.drugabuse.gov. NIDA’s media guide can be found at https://drugabuse.gov/mediaguide, and its easy-to-read website can be found at https://www.easyread.drugabuse.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health®

###

Institute/Center

National Institute on Drug Abuse (NIDA)

Contact

NIDA Press Office
301-443-6245

Connect with Us

  • Subscribe to news releases
  • RSS Feed

Connect with Us

  • Contact Us
  • X
  • Facebook
  • Instagram
  • YouTube
  • Flickr
  • More Social Media from NIH

Footer

  • NIH Home
  • Virtual Tour
  • En Español
  • Visitor Information
  • Frequently Asked Questions
  • Privacy Policy
  • Disclaimers
  • Accessibility
  • NIH Website Archives
  • Nondiscrimination Notice
  • Freedom of Information Act
  • No Fear Act
  • HHS Vulnerability Disclosure
  • Office of Inspector General
  • USA.gov

NIH…Turning Discovery Into Health®

National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892

U.S. Department of Health and Human Services

Back to Top